Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

被引：0
|
作者：
Osmolovskaya, Yu. F. [1 ]
Zhirov, I. V. [1 ]
Tereshchenko, S. N. [1 ]
机构：
[1] Minist Hlth Russia, AL Myasnikov Inst Clin Cardiol, Dept Myocardial Dis & Heart Failure, Russian Cardiol Res & Prod Complex, Moscow, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2015年 / 87卷 / 09期
关键词：
aldosterone; mineralocorticoid receptor antagonists; chronic heart failure; PRESERVED EJECTION FRACTION; CHRONIC KIDNEY-DISEASE; SELECTIVE ALDOSTERONE BLOCKER; MILD PATIENTS HOSPITALIZATION; DOUBLE-BLIND; BAY; 94-8862; MYOCARDIAL-INFARCTION; EUROPEAN-SOCIETY; ASSOCIATION HFA; EMPHASIS-HF;
D O I：
10.17116/terarkh201587977-83
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventricular systolic function and the advent and practical introductions of safer new-generation MCRA remain to be answered.
引用
收藏
页码：77 / 83
页数：7
相关论文
共 50 条
  • [21] Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers
    Karthigan, Nikshay
    Lockwood, Siobhan
    White, Anthony
    Yang, Jun
    Young, Morag J.
    JOURNAL OF ENDOCRINOLOGY, 2022, 253 (03) : R65 - R76
  • [22] AT II receptor antagonists in chronic heart failure treatment
    Gurevich, M. A.
    RUSSIAN JOURNAL OF CARDIOLOGY, 2009, (02): : 73 - 78
  • [23] Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives
    Pitt, Bertram
    Ferreira, Joao Pedro
    Zannad, Faiez
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2017, 3 (01) : 48 - 57
  • [24] The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure
    Bertram Pitt
    Heart Failure Reviews, 2012, 17 : 573 - 579
  • [25] The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure
    Pitt, Bertram
    HEART FAILURE REVIEWS, 2012, 17 (4-5) : 573 - 579
  • [26] Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
    Holmdahl, Anna Jonsson
    Norberg, Helena
    Valham, Fredrik
    Bergdahl, Ellinor
    Lindmark, Krister
    PLOS ONE, 2021, 16 (10):
  • [27] Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
    Abe, Takuro
    Jujo, Kentaro
    Kametani, Motoko
    Minami, Yuichiro
    Fukushima, Noritoshi
    Saito, Katsumi
    Hagiwara, Nobuhisa
    ESC HEART FAILURE, 2020, 7 (05): : 2711 - 2724
  • [28] New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
    Irene Capelli
    Lorenzo Gasperoni
    Marco Ruggeri
    Gabriele Donati
    Olga Baraldi
    Giovanni Sorrenti
    Maria Turchese Caletti
    Valeria Aiello
    Giuseppe Cianciolo
    Gaetano La Manna
    Journal of Nephrology, 2020, 33 : 37 - 48
  • [29] Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
    Ferreira, Joao Pedro
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Schueler, Elke
    Steubl, Dominik
    Zeller, Cordula
    Januzzi, James L.
    Pocock, Stuart
    Packer, Milton
    Anker, Stefan D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (12) : 1129 - 1137
  • [30] Prognostic impact of mineralocorticoid receptor antagonists in patients hospitalized for acute heart failure
    Yaku, H.
    Kato, T.
    Morimoto, T.
    Inuzuka, Y.
    Tamaki, Y.
    Yamamoto, E.
    Yoshikawa, Y.
    Ozasa, N.
    Kuwahara, K.
    Kimura, T.
    EUROPEAN HEART JOURNAL, 2019, 40 : 639 - 639
12345